At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
RPL554 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Randomised, Double Blind, Placebo Controlled, Three Way Crossover Study to Assess the Pharmacokinetics of RPL554 Administered to Adult Patients With Cystic Fibrosis.
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA·interventional·Posted Sep 30, 2016·Updated May 21, 2024
In Brief
A Phase 2 clinical trial evaluating RPL554 and Placebo for Cystic Fibrosis. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis. All patients receive all three treatments in a randomised sequence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited Kingdom
CollaboratorsCystic Fibrosis Trust
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartFeb 2017
Primary CompletionNov 2017
TodayJul 2026
First PostedSep 30, 2016
Enrollment StartFeb 8, 2017
Primary CompletionNov 3, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.8 years ago
Interventions
RPL554drug
RPL554 suspension administered using a nebuliser
Placebodrug
Placebo solution administered using a nebuliser